Powder: -20°C for 3 years
In solvent: -80°C for 2 years
BMS-986165 inhibits IL-12/23 and type I IFN pathways[1][2]. BMS-986165 is a highly selective, orally bioavailable allosteric TYK2 inhibitor for the treatment of autoimmune diseases. Which selectively binds to TYK2 pseudokinase (JH2) domain (IC50=1.0 nM) and blocks receptor-mediated Tyk2 activation by stabilizing the regulatory JH2 domain.
Description | BMS-986165 inhibits IL-12/23 and type I IFN pathways[1][2]. BMS-986165 is a highly selective, orally bioavailable allosteric TYK2 inhibitor for the treatment of autoimmune diseases. Which selectively binds to TYK2 pseudokinase (JH2) domain (IC50=1.0 nM) and blocks receptor-mediated Tyk2 activation by stabilizing the regulatory JH2 domain. |
Targets&IC50 | Tyk2 JH2:0.2 nM, JAK1 JH2:1 nM |
In vitro | BMS-986165 maintains excellent potency in human and mouse whole blood (IC50s=13 and 100 nM, respectively). Which shows no significant hERG inhibition in the flux assay (IC50>80 μM).BMS-986165 is differentiated from previous JAK inhibitors due its unique ability to selectively bind to the pseudokinase (JH2) domain of TYK2 and inhibit its function through an allosteric mechanism[1]. |
In vivo | BMS-986165 as a high affinity JH2 ligand and potent allosteric inhibitor of TYK2. In addition to unprecedented JAK isoform and kinome selectivity, BMS-986165 shows excellent pharmacokinetic properties with minimal profiling liabilities and is efficacious in several murine models of autoimmune disease. On the basis of these findings, BMS-986165 appears differentiated from all other reported JAK inhibitors and has been advanced as the first pseudokinase-directed therapeutic in clinical development as an oral treatment for autoimmune diseases[1]. |
Synonyms | BMS-986165 |
Molecular Weight | 425.46 |
Formula | C20H22N8O3 |
CAS No. | 1609392-27-9 |
Powder: -20°C for 3 years
In solvent: -80°C for 2 years
DMSO: 32.5mg/ml (76.39 Mm), Need ultrasonic
( < 1 mg/ml refers to the product slightly soluble or insoluble )
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Deucravacitinib 1609392-27-9 JAK/STAT信号通路 表观遗传 蛋白酪氨酸激酶 干细胞 免疫与炎症 血管生成 IFNAR Interleukin JAK Tyrosine Kinases Janus kinase inhibit Interleukin Related Interferon-alpha/beta receptor BMS 986165 Interferon-α/β receptor BMS-986165 Inhibitor BMS986165 inhibitor